TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) will host a conference call on Thursday, February 26, 2026 at 8:30 AM ET to discuss fourth-quarter and full-year 2025 results and provide a 2026 business outlook.
Michael S. Weiss, Chairman and CEO, will host. A live webcast and a 30-day replay will be available on the company's Investors & Media Events page. Financial results will be issued in a press release prior to the call.
Positive
- None.
Negative
- None.
News Market Reaction – TGTX
In the Feb 23 session, TGTX gained 3.52%, reflecting a moderate positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 31 | Q3 2025 call scheduled | Positive | +2.2% | Announced timing and access details for Q3 2025 earnings call. |
| Jul 30 | Q2 2025 call scheduled | Positive | +2.7% | Set date and logistics for Q2 2025 earnings and business update. |
| Apr 30 | Q1 2025 call scheduled | Positive | +3.8% | Announced first quarter 2025 earnings call and webcast details. |
| Feb 26 | FY 2024 call scheduled | Positive | +0.5% | Scheduled Q4 and full-year 2024 results call and 2025 outlook. |
| Nov 01 | Q3 2024 call scheduled | Positive | +7.3% | Outlined date for Q3 2024 earnings call and business update. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Scheduling earnings calls has historically been followed by modestly positive price reactions, suggesting investors treat these as routine but slightly constructive catalysts.
Over the past year, TG Therapeutics has regularly pre-announced quarterly earnings calls, with five prior conferences,earnings notices from Nov 2024 through Oct 2025. Each outlined timing, access details, and a plan to release financials ahead of the call, hosted by CEO Michael S. Weiss. These events saw positive 24-hour moves ranging from 0.45% to 7.34%, indicating that the market has typically reacted favorably, albeit moderately, to this type of scheduling update.
Key Terms
earnings call financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
| CONTACT: | |
| Investor Relations | |
| Email: ir@tgtxinc.com | |
| Telephone: 1.877.575.TGTX (8489), Option 4 | |
| Media Relations: | |
| Email: media@tgtxinc.com | |
| Telephone: 1.877.575.TGTX (8489), Option 6 | |
